The Association between Leukotriene-Modifying agents Use and Depression
in Adults: A Population-based Analysis of the NHANES from 2007 to 2016
Abstract
Introduction Post-market monitoring has revealed an association
between the use of leukotriene-modifying agents (LTRAs) and an increased
occurrence of neuropsychiatric events. However, the results of
observational studies have been inconclusive. Objective To
assess the potential correlation between LTRAs exposure and depression
in US outpatient adults. Method This population-based
cross-sectional study used data from U.S. adults aged 20 to 59 years
from the National Health and Nutrition Examination Survey (NHANES)
2007-2016 cycle. The Patient Health Questionnaire-9 was used to assess
depression. Multivariable regression was used to evaluate the
association between LTRAs exposure and depression. Results
Among the 9,539 participants (mean age 40.4 years; 56.2% male), 602
(6.3%) were classified as having depression. LTRAs exposure was
associated with a higher prevalence of depression (16.7% [50] vs.
6.0% [552]). In the multivariable logistic regression model LTRAs
exposure was associated with depression (odds ratio [OR], 1.85; 95%
confidence interval [CI], 1.22~2.83). An association
between LTRAs exposure and depression was found in sensitivity analyses
that conducted multivariable linear regression with the PHQ-9 score as a
continuous variable (β, 0.86; 95% CI, 0.39~1.33),
regardless of the PHQ-9 cut-off of 5 or 10, and the multivariable
logistic regression results showed that LTRAs use increased the risk of
depression (OR = 1.51 [95% CI, 1.12~2.05]; OR =
1.85 [95% CI, 1.22~2.83]). Conclusion
Long-term LTRAs exposure is positively associated with depression in the
adult outpatient population in the US. Therefore, the risk for
depression in patients receiving long-term LTRAs treatment should be
considered.